In a nutshell This study aimed to investigate the association between total body irradiation and further breast cancer diagnosis in patients treated with blood or marrow transplantation for leukemia-lymphoma. This study concluded that there is an association between the total body irradiation and an increased risk of breast cancer in certain...
Read MoreType of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor
Evaluating treatment options for pregnant patients with non-Hodgkin lymphoma
In a nutshell This study was carried out to assess the outcomes of pregnant women who have non-Hodgkin lymphoma (NHL). The authors concluded that treating NHL with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens during pregnancy can be considered after the first trimester. Some background NHL...
Read MoreEvaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.
In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT). Some background Lymphoma is a cancer that...
Read MoreOutcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas
In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...
Read MoreBlinatumomab for unresponsive aggressive non-Hodgkin lymphoma
In a nutshell This study looked at using both chemotherapy and blinatumomab (Blincyto) prior to stem cell transplant (SCT) for patients with relapsed or unresponsive aggressive non-Hodgkin lymphoma (NHL). It found that blinatumomab is an effective second salvage for patients who did not fully respond to chemotherapy. Some background NHL is a...
Read MoreDouble CAR T immune therapy for relapsed B cell lymphoma
In a nutshell This initial study looked at using CAR T cells with two targets to treat relapsed B cell non-Hodgkin lymphoma (NHL). It found that this type of immunotherapy was safe and effective, and may cause less inflammation than other types of CAR T cell treatment. Some background Chimeric antigen receptor T (CAR T) cells are a treatment for...
Read MoreHow does COVID-19 affect patients with cancer undergoing chemotherapy?
In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...
Read MoreHow effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?
In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...
Read MoreWhich patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?
In a nutshell This study compared the effectiveness of CAR-T treatment for patients with diffuse large B cell lymphoma (DLBCL). The authors found that while a significant number of all patients benefitted from the treatment, some patients were more likely to benefit from it than others. Some background During initial treatment for DLBCL,...
Read MoreWhich chemotherapy combination causes less kidney damage to patients with non-Hodgkin lymphoma?
In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...
Read MoreHow common are side effects of the heart in patients with non-Hodgkin lymphoma who receive CHOP or R-CHOP chemotherapy?
In a nutshell This study examined how common side effects of the heart, including heart failure, were among patients with non-Hodgkin lymphoma who received CHOP or R-CHOP chemotherapy. The results showed that only a minority developed side effects and that older patients and female patients were more likely to develop them. Some background Both...
Read MoreEvaluating pembrolizumab plus R-CHOP chemotherapy for patients with untreated diffuse large B-cell lymphoma
In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that pembrolizumab can be safely added to R-CHOP, with improved survival outcomes. Some...
Read More